{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115052","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.470373+00:00","generated_at":"2026-05-30T03:26:32.394393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ironwood Q3 revenue down 19% YoY to $91.6M; LINZESS Rx demand +13%","bullets":["GAAP net income $3.6M ($0.02 diluted EPS) vs $15.3M ($0.10) a year ago.","Total revenue $91.6M, down from $113.7M in Q3 2023; cites pricing headwinds.","LINZESS new-to-brand and extended-unit prescriptions each grew 13% YoY.","Apraglutide NDA submission for short bowel syndrome on track for Q1 2025.","Full-year 2024 financial guidance reaffirmed; Adjusted EBITDA $26.2M vs $49.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115052","json":"https://secwatch.observer/filing/0001104659-24-115052.json","markdown":"https://secwatch.observer/filing/0001104659-24-115052.md","text":"https://secwatch.observer/filing/0001104659-24-115052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924115052/0001104659-24-115052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924115052/tm2427582d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:26:32.394393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}